advanced gastrointestinal

• Healthcare
• Pharma & Biotech
• Switzerland

Novartis: Phase III study of Afinitor® shows significant extension of progression-free survival in advanced gastrointestinal or lung neuroendocrine tumors

Study in patients with advanced nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin met primary endpoint[1] Full results…